ImmunoGen Inc.
IMGN
NGS
Sector: Healthcare
Industry: Biotechnology
4.85
USD
0.07
(1.46%)
Optionable: Yes Market Cap: 1,020 M 90-day average vol: 2,941,793
Previous close: 4.78 Open: 4.87 Bid: 5.11 Ask: 5.11
52 week range
3.10 7.77
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 11.40 |
Price per Book TTM ($) | 3.96 |
PE Ratio (TTM) | -6.50 |
Book Value per Share ($) | 0.35 |
5 Year PE Range-25.7 |
Returns
7 Day Return | 8.26% | |
1 Month Return | -5.09% | |
3 Month Return | -1.02% | |
1 Year Return | -17.66% | |
3 Year Return | 109.50% | |
5 Year Return | -38.06% | |
YTD Return | -34.64% |
Risk
Custom Beta One Year | 1.48 |
Custom Beta Three Years | 1.42 |
Beneish M Score | 218.19 |
Altman Z Score | -0.64 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 44.61 |
14 Day SMA ($) | 4.86 |
14 Day EMA ($) | 4.88 |
Money Flow Index | 41.08 |
Average True Range | 0.30 |
50 Day SMA ($) | 5.30 |
200 Day SMA ($) | 5.17 |
ADX | 4.03 |
MACD | -0.20 |
Growth
Free Cash Flow QoQ Growth | 53.92% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 140.00% |
Revenue QoQ Growth | -62.81% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
IMGN Income Statement
Annual
| Jun-13 | Jun-14 | Jun-15 | Jun-16 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 36 M | 60 M | 86 M | 60 M | 22 M | 115 M | 53 M | 82 M | 132 M | 70 M |
| Cost of sales | 82 M | 102 M | 106 M | 143 M | 63 M | 134 M | 167 M | 110 M | 112 M | 32 M |
| Gross operating profit | -52 M | -47 M | -26 M | -88 M | -45 M | -24 M | -121 M | -32 M | 18 M | 35 M |
| Selling Gen & administrative expense | 21 M | 24 M | 28 M | 37 M | 18 M | 34 M | 37 M | 38 M | 39 M | 44 M |
| Research & development expense | 87 M | 107 M | 112 M | 148 M | 67 M | 140 M | 174 M | 115 M | 115 M | 151 M |
| Operating income | -73 M | -72 M | -54 M | -125 M | -63 M | -58 M | -158 M | -71 M | -21 M | -125 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 198000 | 167000 | -847000 | 442000 | -5 M | -21 M | -361000 | -16 M | -277000 | -1 M |
| Pre-tax Income (EBT) | -73 M | -71 M | -61 M | -145 M | -79 M | -96 M | -169 M | -104 M | -44 M | -139 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -73 M | -71 M | -61 M | -145 M | -79 M | -96 M | -169 M | -104 M | -44 M | -139 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -73 M | -71 M | -61 M | -145 M | -79 M | -96 M | -169 M | -104 M | -44 M | -139 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -73 M | -71 M | -61 M | -145 M | -79 M | -96 M | -169 M | -104 M | -44 M | -139 M |
| Depreciation | 5 M | 5 M | 6 M | 5 M | 3 M | 6 M | 7 M | 4 M | 2 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -68 M | -67 M | -50 M | -119 M | -65 M | -73 M | -151 M | -83 M | -19 M | -124 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.87 | -0.83 | -0.71 | -1.67 | -0.91 | -0.98 | -1.21 | -0.7 | -0.25 | -0.68 |
| Diluted EPS total | -0.87 | -0.83 | -0.71 | -1.67 | -0.91 | -0.98 | -1.21 | -0.7 | -0.25 | -0.68 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today